Skip to main content

Table 1 Incidence of ACLF in patients with different previous NUCs treatment experiences

From: Is HBV viral load at admission associated with development of acute-on-chronic liver failure in patients with acute decompensation of chronic hepatitis B related cirrhosis?

NUCs experiences

HBV DNA ad-level

(IU/ml), n (%)

Log (HBV DNA), mean ± SD

MELD scores, mean ± SD

ACLF development, n (%)

<2000

≥2000

n

before admission

after admission

Total

naïve

26 (29.5)

62 (70.5)

4.55 ± 1.71

19.7 ± 8.9

88

22 (25.0)

11 (12.5)

33 (37.5)

maintained

8 (66.7)

4 (33.3)

2.27 ± 2.48

17.5 ± 9.9

12

2 (16.7)

3 (25.0)

5 (41.7)

interrupted

2 (18.2)

9 (81.8)

5.40 ± 1.90

15.4 ± 8.8

11

2 (18.2)

3 (27.3)

5 (45.5)

Total

36 (32.4)

75 (67.6)

4.39 ± 1.97

19.0 ± 9.0

111

26 (23.4)

17 (15.3)

43 (38.7)

  1. 1. NUCs experiences: naïve: antiviral treatment-naïve patients; maintained: patients with sustained long-term NUCs treatments till admission; interrupted: patients with interruption or discontinuation of antiviral treatment after long-term of NUCs therapies
  2. 2. HBV DNA ad-level <2000 IU/ml or ≥ 2000 IU/ml: Fisher’s exact test, P = 0.032
  3. 3. Log(HBV DNA) (logarithm of the serum HBV DNA ad-level): F = 10.150, P = 0.000
  4. 4. MELD scores (MELD scores at admission): F = 1.301, P = 0.276
  5. 5. ACLF development: Fisher’s exact test, P = 0.549; ACLF vs No-ACLF: χ2 = 0.309, P = 0.828; ACLF after admission vs No-ACLF: Fisher’s exact test, χ2 = 2.083, P = 0.353; ACLF before admission vs No-ACLF: Fisher’s exact test, P = 1.000